Stay updated with breaking news from Nasdaq Itos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ITeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Equities researchers at HC Wainwright upped their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.13) for the quarter, up […]
ITeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Wedbush reduced their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.58). Wedbush […]
ITeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 1,690,000 shares, a growth of 11.2% from the March 15th total of 1,520,000 shares. Approximately 5.8% of the company’s stock are sold short. Based on an average trading volume of […]
Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) were down 2.9% on Tuesday . The stock traded as low as $14.11 and last traded at $14.11. Approximately 4,403 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 273,655 shares. The stock had previously closed at $14.53. Wall […]
ITeos Therapeutics (NASDAQ:ITOS – Get Rating) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Volatility and Risk iTeos Therapeutics has a beta of […]